Leqembi gains approval for Alzheimer’s treatment in Israel
The approval of Leqembi (generic name: Lecanemab) in Israel marks a significant milestone, as Israel becomes the sixth territory to endorse the drug for Alzheimer’s treatment after the
ImmunityBio has received approval from the Pharmaceutical Administration Bureau (ISAF) of the Macau Special Administrative Region, China, for Anktiva (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin (BCG) for bladder cancer.
The funding will support ongoing clinical trials for X-Linked Retinitis Pigmentosa (XLRP) and advance the company’s Dry Age-related Macular Degeneration (dAMD) programme. The investment round included contributions from